Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Anika Therapeutics stock | $41.93

Learn how to easily invest in Anika Therapeutics stock.

Anika Therapeutics Inc is a medical devices business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Anika Therapeutics employs 277 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Anika Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANIK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Anika Therapeutics stock price (NASDAQ: ANIK)

Use our graph to track the performance of ANIK stocks over time.

Anika Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$41.93
52-week range$32.04 - $48.37
50-day moving average $40.72
200-day moving average $41.82
Wall St. target price$49.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.90

Buy Anika Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Anika Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anika Therapeutics price performance over time

Historical closes compared with the close of $41.93 from 2021-10-20

1 week (2021-10-14) -0.12%
1 month (2021-09-22) 7.21%
3 months (2021-07-22) 4.85%
6 months (2021-04-22) -2.08%
1 year (2020-10-21) 17.02%
2 years (2019-10-21) -26.40%
3 years (2018-10-19) 2.27%
5 years (2016-10-21) 43.65

Is Anika Therapeutics under- or over-valued?

Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Anika Therapeutics's PEG ratio

Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1868. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Anika Therapeutics's EBITDA

Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.4 million.

The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.

Anika Therapeutics financials

Revenue TTM $136.8 million
Gross profit TTM $80.1 million
Return on assets TTM -1.03%
Return on equity TTM -4.42%
Profit margin -9.28%
Book value $19.89
Market capitalisation $600.9 million

TTM: trailing 12 months

Shorting Anika Therapeutics shares

There are currently 1.1 million Anika Therapeutics shares held short by investors – that's known as Anika Therapeutics's "short interest". This figure is 11.8% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting Anika Therapeutics shares can be evaluated.

Anika Therapeutics's "short interest ratio" (SIR)

Anika Therapeutics's "short interest ratio" (SIR) is the quantity of Anika Therapeutics shares currently shorted divided by the average quantity of Anika Therapeutics shares traded daily (recently around 77827.777777778). Anika Therapeutics's SIR currently stands at 13.68. In other words for every 100,000 Anika Therapeutics shares traded daily on the market, roughly 13680 shares are currently held short.

However Anika Therapeutics's short interest can also be evaluated against the total number of Anika Therapeutics shares, or, against the total number of tradable Anika Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anika Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Anika Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0746% of the tradable shares (for every 100,000 tradable Anika Therapeutics shares, roughly 75 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Anika Therapeutics.

Find out more about how you can short Anika Therapeutics stock.

Anika Therapeutics share dividends

We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.

Anika Therapeutics share price volatility

Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $32.04 up to $48.37. A popular way to gauge a stock's volatility is its "beta".

ANIK.US volatility(beta: 1.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 1.2122. This would suggest that Anika Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Anika Therapeutics overview

Anika Therapeutics, Inc. , together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

What percentage of Anika Therapeutics is owned by insiders or institutions?
Currently 0.859% of Anika Therapeutics shares are held by insiders and 93.272% by institutions.
How many people work for Anika Therapeutics?
Latest data suggests 277 work at Anika Therapeutics.
When does the fiscal year end for Anika Therapeutics?
Anika Therapeutics's fiscal year ends in December.
Where is Anika Therapeutics based?
Anika Therapeutics's address is: 32 Wiggins Avenue, Bedford, MA, United States, 01730
What is Anika Therapeutics's ISIN number?
Anika Therapeutics's international securities identification number is: US0352551081
What is Anika Therapeutics's CUSIP number?
Anika Therapeutics's Committee on Uniform Securities Identification Procedures number is: 035255108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site